Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 1/2 1

Status

Recruiting 6Completed 6Active not recruiting 5Withdrawn 3Unknown 3Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 4Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 200Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Neoplasms × Lenalidomide × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
11 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT01750983 2019-02-25

Ipilimumab and Lenalidomide in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
101 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡